Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Vyas

Showing results (71-80 of 297) with videos related to

Pageof 30
Sort By:
Medicinal Chemistry (Shariqah (United Arab Emirates))|August 28, 2012
Synthesis and QSAR modeling of novel benzimidazolo thiazolidinones, thiazinones and 5-arylidene-2-imino thiazolidinones as antibacterial agentsManjunath Ghate, Praveena Devi, Jignesh Parikh, et al.
Journal of Dairy Science|August 31, 2002
Scale-up of native beta-lactoglobulin affinity separation processH K Vyas, J M Izco, R Jiménez-Flores
Acta Crystallographica. Section C, Crystal Structure Communications|April 30, 1999
Troglitazone, an euglycemic antidiabetic drugK Vyas, A Sivalakshmidevi, C Prabhakar, et al.
British Heart Journal|May 1, 1993
Mycotic aneurysm of left subclavian arteryS K Vyas, N W Law, C A Loehry
SAR and QSAR in Environmental Research|March 7, 2014
Design, synthesis, pharmacological evaluation and in silico ADMET prediction of novel substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonists based on predictive 3D QSAR modelsV K Vyas, N Gupta, M Ghate, et al.
Current Computer-Aided Drug Design|September 10, 2013
3D QSAR studies on substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonistVivek K Vyas, Manjunath Ghate, Chetan Chintha, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 4, 2016
Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activityShraddha V Bhadada, Vivek K Vyas, Ramesh K Goyal
Science (New York, N.Y.)|December 2, 1988
Sugar and signal-transducer binding sites of the Escherichia coli galactose chemoreceptor proteinN K Vyas, M N Vyas, F A Quiocho
Discovery Medicine|January 20, 2007
Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challengeMansoor M Amiji, Tushar K Vyas, Lipa K Shah
Journal of Biomolecular Structure & Dynamics|June 15, 2021
Structure- and ligand-based drug design methods for the modeling of antimalarial agents: a review of updates from 2012 onwardsVivek K Vyas, Sapna Bhati, Shivani Patel, et al.
Pageof 30

Showing results (71-80 of 297) with videos related to

Sort By:
Pageof 30
Medicinal Chemistry (Shariqah (United Arab Emirates))|August 28, 2012
Synthesis and QSAR modeling of novel benzimidazolo thiazolidinones, thiazinones and 5-arylidene-2-imino thiazolidinones as antibacterial agentsManjunath Ghate, Praveena Devi, Jignesh Parikh, et al.
Journal of Dairy Science|August 31, 2002
Scale-up of native beta-lactoglobulin affinity separation processH K Vyas, J M Izco, R Jiménez-Flores
Acta Crystallographica. Section C, Crystal Structure Communications|April 30, 1999
Troglitazone, an euglycemic antidiabetic drugK Vyas, A Sivalakshmidevi, C Prabhakar, et al.
British Heart Journal|May 1, 1993
Mycotic aneurysm of left subclavian arteryS K Vyas, N W Law, C A Loehry
SAR and QSAR in Environmental Research|March 7, 2014
Design, synthesis, pharmacological evaluation and in silico ADMET prediction of novel substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonists based on predictive 3D QSAR modelsV K Vyas, N Gupta, M Ghate, et al.
Current Computer-Aided Drug Design|September 10, 2013
3D QSAR studies on substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonistVivek K Vyas, Manjunath Ghate, Chetan Chintha, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 4, 2016
Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activityShraddha V Bhadada, Vivek K Vyas, Ramesh K Goyal
Science (New York, N.Y.)|December 2, 1988
Sugar and signal-transducer binding sites of the Escherichia coli galactose chemoreceptor proteinN K Vyas, M N Vyas, F A Quiocho
Discovery Medicine|January 20, 2007
Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challengeMansoor M Amiji, Tushar K Vyas, Lipa K Shah
Journal of Biomolecular Structure & Dynamics|June 15, 2021
Structure- and ligand-based drug design methods for the modeling of antimalarial agents: a review of updates from 2012 onwardsVivek K Vyas, Sapna Bhati, Shivani Patel, et al.
Pageof 30